ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
PLATFORM TECHNOLOGY
EC-18 targets anti-inflammatory
pathway
Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE
CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)
ENGLEWOOD CLIFFS, N.J., March 1, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovat
Enzychem Lifesciences Announces Poster Presentation At AACR Virtual
Annual Meeting 2021
ENGLEWOOD CLIFFS, N.J., Feb. 8, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), a biopharmaceutical company developing innovative medicines to
Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space
ENGLEWOOD CLIFFS, N.J., Jan. 26, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), announced today that NASA’s Human Research Program has